Literature DB >> 21147226

Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Russell R Braeuer1, Maya Zigler, Gabriel J Villares, Andrey S Dobroff, Menashe Bar-Eli.   

Abstract

The molecular changes associated with the transition of melanoma cells from radial growth phase (RGP) to vertical growth phase (VGP) and the metastatic phenotype are not very well defined. However, some of the genes involved in this process and their transcriptional regulation are beginning to be elucidated. For example, the switch from RGP to VGP and the metastatic phenotype is associated with loss of the AP-2α transcription factor. AP-2α regulates the expression of c-KIT, MMP-2, VEGF, and the adhesion molecule MCAM/MUC18. Recently, we reported that AP-2α also regulates two G-protein coupled receptors (GPCRs) PAR-1 and PAFR. In turn, the thrombin receptor, PAR-1, regulates the expression of the gap junction protein Connexin-43 and the tumor suppressor gene Maspin. Activation of PAR-1 also leads to overexpression and secretion of proangiogenic factors such as IL-8, uPA, VEGF, PDGF, as well certain integrins. PAR-1 also cooperates with PAFR to regulate the expression of the MCAM/MUC18 via phosphorylation of CREB. The ligands for these GPCRs, thrombin and PAF, are secreted by stromal cells, emphasizing the importance of the tumor microenvironment in melanoma metastasis. The metastatic phenotype of melanoma is also associated with overexpression and function of CREB/ATF-1. Loss of AP-2α and overexpression of CREB/ATF-1 results in the overexpression of MCAM/MUC18 which by itself contributes to melanoma metastasis by regulating the inhibitor of DNA binding-1 (Id-1). CREB/ATF-1 also regulates the angiogenic factor CYR-61. Our recent data indicate that CREB/ATF-1 regulates the expression of AP-2α, thus, supporting the notion that CREB is an important "master switch" in melanoma progression.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147226      PMCID: PMC3049824          DOI: 10.1016/j.semcancer.2010.12.007

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  95 in total

1.  Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis.

Authors:  Vladislava O Melnikova; Alexandra A Mourad-Zeidan; Dina Chelouche Lev; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2005-11-23       Impact factor: 5.157

Review 2.  Role of AP-2 in tumor growth and metastasis of human melanoma.

Authors:  M Bar-Eli
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

3.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

4.  The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells.

Authors:  H Jiang; J Lin; Z Z Su; M Herlyn; R S Kerbel; B E Weissman; D R Welch; P B Fisher
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

Review 5.  Connexins and gap junctions in mammary gland development and breast cancer progression.

Authors:  Elizabeth McLachlan; Qing Shao; Dale W Laird
Journal:  J Membr Biol       Date:  2007-07-28       Impact factor: 1.843

6.  Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.

Authors:  Gabriel J Villares; Andrey S Dobroff; Hua Wang; Maya Zigler; Vladislava O Melnikova; Li Huang; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

7.  Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis.

Authors:  H Okahara; H Yagita; K Miyake; K Okumura
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

8.  In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.

Authors:  L B Shih; H Xuan; R Aninipot; R Stein; D M Goldenberg
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

9.  Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture.

Authors:  Mary-Ann Pollmann; Qing Shao; Dale W Laird; Martin Sandig
Journal:  Breast Cancer Res       Date:  2005-05-13       Impact factor: 6.466

10.  Regulation of tyrosinase in human melanocytes grown in culture.

Authors:  R Halaban; S H Pomerantz; S Marshall; D T Lambert; A B Lerner
Journal:  J Cell Biol       Date:  1983-08       Impact factor: 10.539

View more
  40 in total

1.  Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness.

Authors:  Njainday Pulo Jobe; Daniel Rösel; Barbora Dvořánková; Ondřej Kodet; Lukáš Lacina; Rosana Mateu; Karel Smetana; Jan Brábek
Journal:  Histochem Cell Biol       Date:  2016-04-21       Impact factor: 4.304

2.  A nine-gene signature predicting clinical outcome in cutaneous melanoma.

Authors:  G Brunner; M Reitz; A Heinecke; A Lippold; C Berking; L Suter; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-09       Impact factor: 4.553

3.  Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.

Authors:  Tadaaki Yamada; Joseph M Amann; Koji Fukuda; Shinji Takeuchi; Naoya Fujita; Hisanori Uehara; Shotaro Iwakiri; Kazumi Itoi; Konstantin Shilo; Seiji Yano; David P Carbone
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

4.  CREB-induced inflammation is important for malignant mesothelioma growth.

Authors:  Catherine M Westbom; Anurag Shukla; Maximilian B MacPherson; Elizabeth C Yasewicz; Jill M Miller; Stacie L Beuschel; Chad Steele; Harvey I Pass; Pamela M Vacek; Arti Shukla
Journal:  Am J Pathol       Date:  2014-08-08       Impact factor: 4.307

5.  Identification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma development.

Authors:  Anne-Lise Steunou; Manuelle Ducoux-Petit; Ikrame Lazar; Bernard Monsarrat; Monique Erard; Catherine Muller; Eric Clottes; Odile Burlet-Schiltz; Laurence Nieto
Journal:  Mol Cell Proteomics       Date:  2012-12-28       Impact factor: 5.911

Review 6.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

Review 7.  Molecular and cellular pathogenesis of melanoma initiation and progression.

Authors:  Tarik Regad
Journal:  Cell Mol Life Sci       Date:  2013-03-27       Impact factor: 9.261

8.  Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors.

Authors:  Federica Sereni; Massimo Dal Monte; Luca Filippi; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-19       Impact factor: 3.000

9.  EPAC-RAP1 Axis-Mediated Switch in the Response of Primary and Metastatic Melanoma to Cyclic AMP.

Authors:  Carlos I Rodríguez; Edgardo Castro-Pérez; Kirthana Prabhakar; Laura Block; B Jack Longley; Jaclyn A Wisinski; Michelle E Kimple; Vijayasaradhi Setaluri
Journal:  Mol Cancer Res       Date:  2017-08-29       Impact factor: 5.852

10.  Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.

Authors:  Walburga Croteau; Molly H Jenkins; Siying Ye; David W Mullins; Constance E Brinckerhoff
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.